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The effects of estradiol (E2) on urodynamic parameters were studied with twenty 
16-month-old female Wistar rats.  They were divided into 4 groups, i.e., Group I: un-
treated; Groups II and III: treated with E2 for 4 and 8 weeks, respectively; Group IV: 
treated with a placebo for 8 weeks.  After treatment, we measured their plasma E2 levels, 
and recorded their voiding behavior for 24 h.  Cystometry was performed and urody-
namic parameters were analyzed.  Particularly, bladder capacity as well as voided vol-
ume and frequency were surveyed.  The results obtained were compared among groups. 
Levels of bladder capacity in the E2-replaced groups (Groups II, 0.52 ± 0.14 mL and 
Groups III, 0.58 ± 0.09 mL) were signiﬁcantly (P < 0.05) higher than in the other groups 
(Group I, 0.38 ± 0.09 mL and Group IV, 0.40 ± 0.11 mL) respectively.  The average void-
ed volume was signiﬁcantly (P < 0.05) higher in the E2-replaced groups (Groups II, 1.06 
± 0.22 mL and Groups III, 1.01 ± 0.16 mL) than in Group IV (0.79 ± 0.15 mL), respec-
tively.  Concerning the number of daily micturition per day, a signiﬁcant difference (P < 
0.05) was observed only between Group III (14.2 ± 2.7) and Group IV (18.8 ± 3.7). This 
suggests that E2-replacement therapy positively affects bladder function.  
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Urinary incontinence is a debilitating problem par-
ticularly prevalent in elderly women.  Changes in 
bladder function, associated with such postmeno-
pausal states as detrusor instability, stress urinary 
incontinence, and a propensity toward urinary tract 
infection, are believed in part to be due to estrogen 
deﬁciency (Stenberg et al., 1995; Thom and Brown, 
1998).  Lower urinary tract and pelvic floor tis-
sues are known to be estrogen sensitive because 
estrogen receptors are located throughout the blad-
der and urethra (Batra and Iosif, 1983; Klutke and 
Bergman, 1995).  For several reasons, it is hypoth-
esized that estrogen replacement therapy may be 
useful in treating urinary incontinence.  In women 
suffering from stress incontinence, estrogen is ex-
pected to reverse the effects of urethral atrophy, 
improving coaptation, and therefore increasing ure-
thral closure pressure (Fantl et al., 1996).  Further-
more, because estrogen has also been implicated 
in raising the sensory threshold of the bladder to 
cholinergic stimulation, estrogen replacement ther-
apy may be equally useful for detrusor instability 
(Ekstrom et al., 1993; Fantl et al., 1996).
 To date, research on the success of estrogen 
replacement therapy for postmenopausal bladder 
dysfunction has been saddled with controversy be-
cause many studies are based on subjective reports. 
As early as 1941, Salmon et al. (1941) reported suc-
cessful outcomes in postmenopausal women treated 
with intramuscular estrogen replacement therapy. 
Abbreviation:  E2, estradiol.
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Other investigators reported similar results (Rud, 
1980).
 Animal studies have shed light on the role of 
estrogen in bladder function.  Longhurst et al. (1992) 
found that estrogen treatment actually increases 
detrusor sensitivity and improves bladder construc-
tion.  We studied the urodynamic changes associat-
ed with estrogen depletion and replacement therapy. 
In the current study we measured voiding behavior 
and cystometry and assessed estrogen treatment. 
 
Materials and Methods
Animals
All animal experiments were performed in ac-
cordance with the Tottori University Committee 
Guidelines for Animal Experimentation.  We di-
vided 20 female Wistar rats aged 16 months into 4 
groups of 5 animals each.  A silastic tube (inside di-
ameter = 2.5 mm, length = 30 mm, Kaneda Medix, 
Osaka, Japan, catalog number 100-2N) containing 
sesame oil (Sigma-Aldlich, St.Louis, MO, catalog 
number S3547) was subcutaneously planted in 3 
groups.  Ovariectomies were not performed in any 
group.  Group I rats received no treatment.  Groups 
II and III had implantation done with tubes con-
taining 2.50 mg of estradiol (E2) for 4 weeks and 8 
weeks, respectively.  Group IV rats were implanted 
only with sesame oil without E2 for 8 weeks by the 
same methods as Groups II and III (Ohata, 2002). 
All animals were kept in an air-conditioned room 
lighted 12 h a day and allowed access to food and 
water ad libitum.  At the end of experiment, mictu-
rition behavior in a metabolic cage was monitored 
and a cystometry under urethane anesthesia was 
performed.  After that, blood was taken to measure 
plasma E2.
Measurement of plasma E2
Plasma E2 concentrations were assessed by radio-
immunoassay with a Tokyo SRL kit.  After the rats 
were anesthetized with a subcutaneous injection of 
1.0 g/kg urethane, a 2.5 mL amount of blood was 
taken from the heart and was placed in a cyclone 
separator to measure plasma E2 concentration levels.
 
Voiding behavior study
Each rat was placed in a metabolic cage containing 
a urine collection funnel to record their voiding be-
havior.  We designed these so that the urine moved 
through a duct downward to a 250-mL plastic 
beaker, placed on an electronic balance (HF200, 
A.N.D., Tokyo, Japan) connected to a personal 
computer (Macintosh iBook G3, Apple Computer, 
Inc., Cupertino, CA) via a multiport controller 
(Maclab/400, AD Instruments, Castle Hill, Austra-
lia).  The cumulative weight of the collected urine 
was then monitored.  Voided volume and frequency 
were sampled by the computer every 150 s for 24 h, 
and the data were stored on hard disc.  Monitoring 
per each group started at 1000.  During the 24-h 
observation period, the rats were given water but no 
food. 
Cystometry
Cystometry was performed under urethane anesthe-
sia (1.0 g/kg subcutaneously using a 24-G catheter 
(Terumo, Tokyo, catalog number SR-OT2419C) 
inserted into the apex of the bladder dome to record 
pressure and ﬁll the bladder with physiological sa-
line.  External bladder ﬁlling was carried out using 
an infusion pump (5200, TOP, Tokyo) at a constant 
rate of 0.4 mL/min until voiding was detected.  A 
cystostomy catheter was connected to an external 
pressure transducer (P2310, Gould, Eastlake, OH) 
to measure intravesical pressure, which was record-
ed on a Macintosh Powerbook G3 via a bridge am-
plifier (ML112, AD Instruments) and a multiport 
controller Maclab/400.  During voiding, ﬁlter paper 
was carefully placed at the meatus to absorb the 
voided urine without spillage, and the voided vol-
ume was weighed.  The following parameters were 
evaluated:  bladder capacity, bladder compliance, 
maximum detrusor pressure, voided volume and re-
sidual urine volume.  Maximum detrusor pressure 
was deﬁned as instantaneous pressure minus post-
contraction resting pressure.
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Statistical analysis
Statistical comparison of differences between 
groups was performed using analysis of variance 
and the multiple comparison Fisher sʼ test; P < 0.05 
was considered signiﬁcant. 
 
Results
Plasma E2 levels
Plasma E2 levels in the replaced groups were sig-
niﬁcantly higher than in the untreated and placebo 
groups, respectively.  Between the replaced groups, 
Group III showed significantly higher levels in 
plasma E2 than Group II. There was no signiﬁcant 
difference between Groups I and IV (Table 1).
Table 1.  Plasma E2 levels 
 Group Plasma E2 level (pg/mL)
 I 13.94 ± 3.85      
 II 38.58 ± 6.08
 III  48.86 ± 9.19
 IV  19.32 ± 8.46
 Shown are mean ± SD.
* Signiﬁcant difference: P < 0.05.
Table 2.  Comparison of voiding behavior 
 Group Volume Number of  Average   Maximum 
  excreted per day  micturitions voided volume  voided volume
  (mL) per day (mL) (mL)
 I 15.83 ± 8.42   17.6 ± 3.1   0.87 ± 0.35   1.93 ± 0.66
 II 17.87 ± 6.18   16.4 ± 2.9   1.06 ± 0.22    2.44 ± 0.49
 III 14.70 ± 3.50   14.2 ± 2.7   1.01 ± 0.16   1.69 ± 0.36
 IV 14.11 ± 2.56   18.8 ± 3.7   0.79 ± 0.15   2.26 ± 0.41
 Shown are mean ± SD.
* Signiﬁcant difference: P < 0.05.
 Average voided volume = (volume excreted per day) divided by (number of micturitions per day)
 
Voiding behavior study
The number of micturitions per day significantly 
decreased in Group III compared with Group IV. 
However, there were no differences in volume ex-
creted per day between those groups.  The average 
voided volume in Groups II and III significantly 
increased compared with that in Group IV (Table 2).
 
Cystometry
Bladder capacity signiﬁcantly increased in the E2-
replaced groups compared with the other groups, 
respectively.  Voided volume signiﬁcantly increased 
in the E2-replaced groups compared with that in 
Group IV.  However, bladder compliance showed 
no signiﬁcant differences in the placebo or untreat-
ed groups (Table 3).  
 
Discussion
Wistar rats have a fertility period that lasts until 
approximately 15 months, at which time the estrous 
cycle ceases (Handa et al., 1987; Shulman et al., 
1987; Albert et al., 1991).  Albert et al. (1991) found 
that a plasma E2 level of 15 pg/mL was slightly 
below the mean level of E2 present throughout the 
estrous cycle in Wistar rats that maintained normal 
* *
*
*
*
*
*
*
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body weight. In the present study, plasma E2 levels 
in Group I were slightly lower than 15 pg/mL, as 
expected; in Group IV, the levels just exceeded 15 
pg/mL, which were slightly higher than expected 
at such an age.  This may have been caused by the 
tube plantation, but the difference between groups 
was not signiﬁcant.  Groups II and III, which re-
ceived estrogen replacement, showed significant 
increases in plasma E2 levels, achieving levels of 
over 30 and 40 pg/mL, respectively.  Therefore, the 
E2 replacement method in this experiment provided 
adequate levels for studying the effects of E2 on rat 
bladders, as reported (Shulman et al., 1987; Albert 
et al., 1991).  In consideration of the signiﬁcant dif-
ference observed between Groups III and IV, the 
increase in plasma E2 levels seemed to be caused 
by E2 replacement rather than tube plantation.
 Voiding behavior changes with age, as dem-
onstrated by increases in voiding frequency (Chun 
et al., 1988).  The present study on voiding behav-
ior proved no differences in volume excreted per 
day.  The number of daily micturitions signiﬁcantly 
decreased, and average voided volume increased 
in Group III compared with that in Group IV.  It 
stands to reason that frequent urination improved 
due to an increase in average micturition.  In the 
present Wistar rats, E2 replacement affected the 
improvement of bladder function.  The difference in 
maximum voided volume was signiﬁcant between 
Groups II and III.  The underlying cause of this 
difference remains to unknown, but the parameters 
of maximum micturition had little reference to the 
change of voiding behavior for E2 replacement. 
Along with that, cystometry demonstrated that E2-
replaced groups experienced signiﬁcantly increased 
bladder capacity and voided volume compared with 
Group IV.  E2-replaced groups also showed an in-
creased tendency toward bladder compliance, but 
this was not signiﬁcant in our study.  Furthermore, 
we observed a signiﬁcant difference in maximum 
detrusor pressure between Groups I and III, and 
in residuals urine volume between Groups II and 
IV, which might be caused by E2 replacement. 
Because there was an age-based bias in sampling 
the above groups, intra-group examination of E2 
effects was statistically inappropriate.  The results 
of voiding behavior and cystometry showed an 
improvement in bladder function, correlatively. 
There was no signiﬁcant difference in urodynamic 
parameters between Groups II and III.  The term 
of E2 replacement affected the plasma E2 levels; 
however, the plasma E2 levels after 4 weeks of E2 
replacement showed equivalent improvement of 
bladder function to those after 8 weeks of replace-
ment. 
 According to previous reports, ovariectomized 
animals had a decrease in the smooth muscle densi-
ty in the bladders (Hashimoto et al., 1999), and E2-
replaced groups showed increases in the smooth 
muscle content of the bladder (Rocha et al., 2002; 
Table 3.  Comparison of urodynamic parameters 
 Group Bladder Maximum Voided Residual Bladder
  capacity  detrusor pressure volume urine volume compliance
  (mL) (kPa) (mL) (mL) (mL/kPa) 
 I   0.38 ± 0.09 25.4 ± 3.4 0.32 ± 0.09  0.13 ± 0.02 0.05 ± 0.02
 II  0.52 ± 0.14 28.3 ± 2.4 0.39 ± 0.75  0.09 ± 0.07  0.08 ± 0.02
 III  0.58 ± 0.09 30.9 ± 4.9  0.36 ± 0.10  0.15 ± 0.04 0.07 ± 0.01
 IV  0.40 ± 0.11 30.7 ± 1.5 0.26 ± 0.02  0.22 ± 0.09 0.05 ± 0.03
 Shown are mean ± SD.  
* Signiﬁcant difference; P < 0.05.
*
*
*
*
*
*
*
*
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Hikita et al., 2004).  The increase in smooth mus-
cles of the bladder may improve bladder contrac-
tion.  These researchers supposed that E2 replace-
ment improved voiding behavior and urodyanamic 
parameters.
 E2 replacement therapy might prevent apop-
tosis in the bladder and would influence voiding 
behavior (Cockayne et al., 2000; Wotherspoon and 
Winter, 2000; Ohata et al., 2002).  Ohata et al. 
(2002) studied effects of E2 on apoptosis, but they 
observed no significant difference in the dose or 
replacement term of E2.  In the present study, we 
observed no difference in the term of E2 replace-
ment.  Effects on the dose of E2 need to be studied 
further.
 The results obtained suggest that hormone 
replacement therapy may improve the problem of 
urgent and frequent urination in older women. 
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